Wegovy is under FDA review for heart failure with preserved ejection fraction

Wegovy (semaglutide) remains under review at the FDA for heart failure with preserved ejection fraction, or HFpEF, a condition common in people with obesity ^[1]. If cleared, it would give semaglutide an indication that no competing GLP-1 medicine currently holds ^[1].

HFpEF is a form of heart failure in which the heart's main pumping chamber squeezes normally but does not relax and fill the way it should. It accounts for more than half of all heart failure cases in the United States and is becoming more common ^[2]. Most people with HFpEF have overweight or obesity, and research increasingly points to excess weight as a driver of the condition rather than just something that happens alongside it ^[2]. Until now, no therapy has been approved specifically to target obesity-related HFpEF ^[2].

The evidence behind the FDA review comes largely from the STEP-HFpEF trial, published in the New England Journal of Medicine ^[2]. That study randomly assigned 529 people with HFpEF and a body mass index of 30 or higher to weekly injections of semaglutide at 2.4 mg or to a placebo for 52 weeks ^[2]. Participants on semaglutide saw their symptom scores, measured on the Kansas City Cardiomyopathy Questionnaire, improve by 16.6 points, compared with 8.7 points for those on placebo, a gap of 7.8 points ^[2]. On this scale, higher numbers mean fewer symptoms and physical limits ^[2]. Body weight dropped by an average of 13.3% in the semaglutide group versus 2.6% with placebo ^[2]. People taking semaglutide also walked farther in six minutes (21.5 meters more, versus 1.2 meters for placebo) and had a 43.5% drop in C-reactive protein, a marker of inflammation, compared with a 7.3% drop on placebo ^[2]. Serious adverse events were less frequent with semaglutide, reported in 13.3% of that group versus 26.7% on placebo ^[2].

The HFpEF review is one of several ways GLP-1 drugs are moving beyond diabetes and weight loss. Ozempic (semaglutide) is separately under FDA review for peripheral artery disease, based on studies showing improved walking distance and quality of life ^[1]. Novo Nordisk has also filed for approval of a higher, 7.2 mg dose of Wegovy, and for CagriSema, a combination of semaglutide and cagrilintide, with an FDA decision on CagriSema expected sometime in 2026 ^[1].

Why it matters for patients

HFpEF is hard to treat, and doctors have had few options built specifically around the role obesity plays in the disease ^[2]. If Wegovy's HFpEF indication is approved, it would give people with obesity and this type of heart failure documented data — including symptom scores, walking distance, and weight loss figures from a controlled trial — to discuss with their care teams ^[2]. It would also mark the first drug indication of its kind, since no other GLP-1 medicine currently carries this specific approval ^[1]. That distinction could matter for insurance coverage decisions and for how doctors and patients weigh treatment options, though the sources reviewed do not detail how insurers might respond to a new indication.

The trial data also show a pattern seen across several GLP-1 studies: meaningful weight loss paired with functional improvements, alongside fewer serious adverse events in the treatment group than in the placebo group in this particular trial ^[2]. Whether those results generalize to broader real-world use, and what the final FDA decision and timeline will be, is not addressed in these sources.

What happens next

The FDA review of Wegovy for HFpEF is ongoing, with no decision date confirmed in these sources ^[1]. Separately, a decision on Novo Nordisk's CagriSema is expected sometime in 2026, and the FDA is also reviewing Ozempic for peripheral artery disease and a higher, 7.2 mg dose of Wegovy ^[1].